Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.
Risk and Volatility
Eton Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7, indicating that its stock price is 600% more volatile than the S&P 500.
Earnings & Valuation
This table compares Eton Pharmaceuticals and Incannex Healthcare”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eton Pharmaceuticals | $105.59 million | 15.28 | -$4.60 million | $1.51 | 37.39 |
| Incannex Healthcare | $90,000.00 | 312.36 | -$19.30 million | ($1.69) | -1.33 |
Eton Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for Eton Pharmaceuticals and Incannex Healthcare, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eton Pharmaceuticals | 0 | 1 | 4 | 1 | 3.00 |
| Incannex Healthcare | 2 | 0 | 1 | 0 | 1.67 |
Eton Pharmaceuticals presently has a consensus target price of $77.00, suggesting a potential upside of 36.38%. Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 703.57%. Given Incannex Healthcare’s higher probable upside, analysts clearly believe Incannex Healthcare is more favorable than Eton Pharmaceuticals.
Profitability
This table compares Eton Pharmaceuticals and Incannex Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eton Pharmaceuticals | 35.35% | 144.74% | 48.94% |
| Incannex Healthcare | N/A | -25.62% | -24.46% |
Summary
Eton Pharmaceuticals beats Incannex Healthcare on 12 of the 15 factors compared between the two stocks.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
